RxDoctor Payments Data

Melodie Lin

Family · Manhasset, NYNPI 1598313025

Payments from drug & device makers

$2,883in general payments, 2019–2025

Across 55 payments — averaging $52.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$734
  • Scpharmaceuticals Inc.$433
  • Abbott$415
  • Novartis$351
  • Biotronik Inc.$346
  • Merck$125
  • plus $480 from 7 others

What the payments were for

  • Food & beverage$2,883100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,883 in reported general payments places this provider in the 85th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$8,125
Medicare patients
49
Services billed
65

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan216$241,010
FarxigaDapagliflozin Propanediol137$130,994
LokelmaSodium Zirconium Cyclosilicate28$24,233
JardianceEmpagliflozin22$22,680
EliquisApixaban20$17,265
Metoprolol Succinate225$3,538
Bumetanide47$1,393
Torsemide64$1,282
Spironolactone187$1,143
Carvedilol89$878
Isosorbide Dinitrate20$767
Atorvastatin Calcium40$486
Hydralazine Hcl39$389
Isosorbide Mononitrate ErIsosorbide Mononitrate24$178
Furosemide64$174

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$351$241,010216 claims
AstraZenecaFarxiga, Lokelma$734$155,227165 claims
Boehringer IngelheimJardiance$18$22,68022 claims
PfizerEliquis$119$17,26520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,883 family providers in New York.

Other family in Manhasset

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →